Role of new oral antithrombin in management of thrombophilia presented with multiple infarctions (cerebral, myocardial and pulmonary embolism)
Background: Thromboembolic disease is a major cause of mortality and morbidity Current anticoagulant therapies have several caveats in the clinical use. New oral antithrombin (Dabigatran) provides comparable or superior thromboprophylaxis in multiple thromboembolic disease indications compared to st...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2015-01-01
|
| Series: | Egyptian Journal of Chest Disease and Tuberculosis |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0422763814200537 |
| _version_ | 1819205878454157312 |
|---|---|
| author | Mohamed Abdelwahab Ayman El-Dib Mohamed Hantera Ayman A. Al-azzouny |
| author_facet | Mohamed Abdelwahab Ayman El-Dib Mohamed Hantera Ayman A. Al-azzouny |
| author_sort | Mohamed Abdelwahab |
| collection | DOAJ |
| description | Background: Thromboembolic disease is a major cause of mortality and morbidity Current anticoagulant therapies have several caveats in the clinical use. New oral antithrombin (Dabigatran) provides comparable or superior thromboprophylaxis in multiple thromboembolic disease indications compared to standard of care.
Aim of this work: To evaluate the role of a new oral antithrombin, in management of thrombophilia presented with multiple infarctions (cerebral infarction, myocardial infarction, pulmonary embolism or infarction).
Patient and methods: This work was done on 100 patients with thrombophilia associated with multiple infarctions (cerebral infarction, myocardial infarction, pulmonary embolism or infarction). They were divided into 2 groups Group I: treated by LMW heparin. Group II: treated by dabigatran. The following was done for all patients. Thorough history taking, complete physical examination, investigations including CT, D Dimer, INR, APTT, Platelet count, Chest X ray P/A and lateral view, CT chest and/or Brain, ECG, CKMB and troponin when needed.
Results: The percentage of Stroke/TIA, AF/MI, PE, mixed and peripheral thrombotic events were 30, 24, 23, 26 and 6 patients respectively. |
| first_indexed | 2024-12-23T04:58:42Z |
| format | Article |
| id | doaj.art-ac358ca5c2e64352b5c5d97873e2dd74 |
| institution | Directory Open Access Journal |
| issn | 0422-7638 |
| language | English |
| last_indexed | 2024-12-23T04:58:42Z |
| publishDate | 2015-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Egyptian Journal of Chest Disease and Tuberculosis |
| spelling | doaj.art-ac358ca5c2e64352b5c5d97873e2dd742022-12-21T17:59:16ZengWolters Kluwer Medknow PublicationsEgyptian Journal of Chest Disease and Tuberculosis0422-76382015-01-0164125525910.1016/j.ejcdt.2014.11.010Role of new oral antithrombin in management of thrombophilia presented with multiple infarctions (cerebral, myocardial and pulmonary embolism)Mohamed Abdelwahab0Ayman El-Dib1Mohamed Hantera2Ayman A. Al-azzouny3Department of Chest Dis., Tanta University, EgyptDepartment of Chest Dis., Tanta University, EgyptDepartment of Chest Dis., Tanta University, EgyptDepartment of Neurology Medicine, Misr University for Sciences and Technology, EgyptBackground: Thromboembolic disease is a major cause of mortality and morbidity Current anticoagulant therapies have several caveats in the clinical use. New oral antithrombin (Dabigatran) provides comparable or superior thromboprophylaxis in multiple thromboembolic disease indications compared to standard of care. Aim of this work: To evaluate the role of a new oral antithrombin, in management of thrombophilia presented with multiple infarctions (cerebral infarction, myocardial infarction, pulmonary embolism or infarction). Patient and methods: This work was done on 100 patients with thrombophilia associated with multiple infarctions (cerebral infarction, myocardial infarction, pulmonary embolism or infarction). They were divided into 2 groups Group I: treated by LMW heparin. Group II: treated by dabigatran. The following was done for all patients. Thorough history taking, complete physical examination, investigations including CT, D Dimer, INR, APTT, Platelet count, Chest X ray P/A and lateral view, CT chest and/or Brain, ECG, CKMB and troponin when needed. Results: The percentage of Stroke/TIA, AF/MI, PE, mixed and peripheral thrombotic events were 30, 24, 23, 26 and 6 patients respectively.http://www.sciencedirect.com/science/article/pii/S0422763814200537Thromboembolic diseaseOral antithrombinThrombophliaThromboprophylaxisDabigatran |
| spellingShingle | Mohamed Abdelwahab Ayman El-Dib Mohamed Hantera Ayman A. Al-azzouny Role of new oral antithrombin in management of thrombophilia presented with multiple infarctions (cerebral, myocardial and pulmonary embolism) Egyptian Journal of Chest Disease and Tuberculosis Thromboembolic disease Oral antithrombin Thrombophlia Thromboprophylaxis Dabigatran |
| title | Role of new oral antithrombin in management of thrombophilia presented with multiple infarctions (cerebral, myocardial and pulmonary embolism) |
| title_full | Role of new oral antithrombin in management of thrombophilia presented with multiple infarctions (cerebral, myocardial and pulmonary embolism) |
| title_fullStr | Role of new oral antithrombin in management of thrombophilia presented with multiple infarctions (cerebral, myocardial and pulmonary embolism) |
| title_full_unstemmed | Role of new oral antithrombin in management of thrombophilia presented with multiple infarctions (cerebral, myocardial and pulmonary embolism) |
| title_short | Role of new oral antithrombin in management of thrombophilia presented with multiple infarctions (cerebral, myocardial and pulmonary embolism) |
| title_sort | role of new oral antithrombin in management of thrombophilia presented with multiple infarctions cerebral myocardial and pulmonary embolism |
| topic | Thromboembolic disease Oral antithrombin Thrombophlia Thromboprophylaxis Dabigatran |
| url | http://www.sciencedirect.com/science/article/pii/S0422763814200537 |
| work_keys_str_mv | AT mohamedabdelwahab roleofneworalantithrombininmanagementofthrombophiliapresentedwithmultipleinfarctionscerebralmyocardialandpulmonaryembolism AT aymaneldib roleofneworalantithrombininmanagementofthrombophiliapresentedwithmultipleinfarctionscerebralmyocardialandpulmonaryembolism AT mohamedhantera roleofneworalantithrombininmanagementofthrombophiliapresentedwithmultipleinfarctionscerebralmyocardialandpulmonaryembolism AT aymanaalazzouny roleofneworalantithrombininmanagementofthrombophiliapresentedwithmultipleinfarctionscerebralmyocardialandpulmonaryembolism |